-
Jun 6, 2024 | 
nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more
AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).
-
Jun 6, 2024 | nature.com | Dong-Anh Khuong-Quang |Chelsea Mayoh |Marie Wong |Sumanth Nagabushan |Veronica Yeung |Natacha Omer | +15 more
AbstractRecent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT).
-
Oct 31, 2023 | 
frontiersin.org | Cellworks Group |David Eisenstat |Hiroaki Wakimoto |Rebecca Brown
BackgroundLeptomeningeal spread of glioblastoma (LM-GBM) is a life-threatening disease renowned for dire neurological sequelae and short median survival of 1.6 to 3.8 months (1). Though responses to chemotherapy are documented and generally favor a disposition of intervention, single agents accomplish relatively little against complex diseases like LM-GBM.
-
Oct 12, 2023 | 
frontiersin.org | David Eisenstat
The most frequent primary intracranial tumour, glioma causes severe morbidity and mortality. The survival rate is still dismal despite substantial research improvements in molecular processes, diagnostics, and therapy strategies. The occurrence and progression of gliomas as well as the results of anti-tumor immunotherapy are all directly tied to the very varied immune microenvironment of gliomas.
-
Sep 29, 2023 | 
frontiersin.org | David Eisenstat
Malignant primary brain tumors constitute around 30% of all primary brain tumor diagnoses in the United States. Unfortunately, these type of tumors still have a fatal prognosis despite advancements in the neuro-oncological toolbox. Although a multimodal therapy approach is the current gold standard, malignant primary brain tumors display a complex intratumoral heterogeneity.
-
Sep 1, 2023 | 
frontiersin.org | Aligarh Muslim |David Eisenstat
This Research Topic considers possible new advances regarding the contribution of transcription factors, stem cell markers and epigenetic regulation to the phenomenon of resistance to chemotherapy in brain tumors. Glioblastoma and medulloblastoma are the most common malignant brain tumors, typically occurring in adults and children, respectively.
-
Aug 8, 2023 | 
cockroachlabs.com | David Eisenstat
CockroachDB recently gained support for Unicode collation, a standard for ordering strings in the different ways that our users around the world expect. This post describes the motivation for Unicode collation as well as the implementation challenges in providing collated strings as a first-class type. Collated strings are documented here.
-
Aug 8, 2023 | 
frontiersin.org | David Eisenstat
Aldo Spallone*Institute of Bioorganic Chemistry (IBKh) Institute, Russian Academy of Sciences (RAS), Moscow, RussiaGlioblastoma (GBM) remains one of the most difficult to treat diseases in the field of oncology, and in neurooncology in particular. This Editorial focuses on the role of surgery and includes the four manuscripts included in the Research Topic “Modern Neurosurgical Management of Gliomas, including Local Therapies”.
-
Jun 7, 2023 | 
frontiersin.org | David Eisenstat
Hongmin Bai*† and Che Jiang†Department of Neurosurgery, General Hospital of Southern Theater Command, Guangzhou, Guangdong, ChinaPresently, maximal-safe resection is still the primary pursuit for surgically treating glioma. Accordingly, there are a variety of novel techniques being developed. Therefore, this Research Topic aimed to summarize advances in glioma surgery along with emerging auxiliary techniques.
-
May 19, 2023 | 
frontiersin.org | Shaanxi Normal |Rudbeck Laboratory |David Eisenstat
The blood-brain barrier (BBB) is a specialization of brain endothelial cells (ECs) that hinders the effective delivery of drugs into the brain by establishing EC junctions, sealing EC-EC contacts, pumping drugs out by active transport, and suppressing transcytosis (1, 2). In brain tumors, blood vessels are abnormal with a heterogeneous and partially intact BBB, known as the blood-tumor barrier (BTB) (1, 3).
